Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CALML3 | P27482 | 6/20 | 0.49 |
| ▸ | MAOA | P21397 | 9/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13760401 | 0.88 | MAOA (0.62) | CYP3A4CYP2C9MAOACYP2D6 | |
| Trifluoroacetic Acid SCHEMBL1381749 | 0.84 | MAOA (0.58) | CYP3A4CYP2C9MAOACYP2D6 | |
| SCHEMBL13089907 | 0.84 | MAOA (0.56) | CALML3MAOA | |
| Trifluoroacetic Acid SCHEMBL1383835 | 0.80 | MAOA (0.52) | CALML3MAOA | |
| SCHEMBL12606546 | 0.80 | CALML3 (0.49) | CYP3A4CYP2C9CALML3MAOA | |
| SCHEMBL13760400 | 0.77 | MAOA (0.52) | CYP3A4CALML3MAOA | |
| Trifluoroacetic Acid SCHEMBL1382546 | 0.76 | CALML3 (0.46) | CYP3A4CYP2C9CALML3MAOA | |
| SCHEMBL18786451 | 0.76 | CALML3 (0.57) | CYP3A4CYP2C9CALML3MAOACYP2D6 | |
| SCHEMBL20528027 | 0.76 | CALML3 (0.57) | CYP3A4CYP2C9CALML3MAOACYP2D6 | |
| SCHEMBL18786544 | 0.76 | CALML3 (0.57) | CYP3A4CYP2C9CALML3MAOACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816379-B2 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2010-10-19 | — | — | US | disclosed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | disclosed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | ALPI, SI, TST | CYP3A4 68/4885CYP2C9 411/4885CALML3 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.